-

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2023

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the first quarter of 2023 of $1.13 per share on the company’s common stock. The dividend is payable on March 7, 2023 to shareholders of record at the close of business on February 21, 2023. The ex-dividend date is February 17, 2023.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Contacts

Johnson & Johnson


Release Versions

Contacts

More News From Johnson & Johnson

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson &...

Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12th, 2026. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available...

Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. The transaction is expected to close within the next few months,...
Back to Newsroom